These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 34157326

  • 21. Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress.
    Yang JH, Kim SC, Kim KM, Jang CH, Cho SS, Kim SJ, Ku SK, Cho IJ, Ki SH.
    Eur J Pharmacol; 2016 Jul 15; 783():92-102. PubMed ID: 27151496
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.
    Nagata H, Hatano E, Tada M, Murata M, Kitamura K, Asechi H, Narita M, Yanagida A, Tamaki N, Yagi S, Ikai I, Matsuzaki K, Uemoto S.
    Hepatology; 2009 Jun 15; 49(6):1944-53. PubMed ID: 19418558
    [Abstract] [Full Text] [Related]

  • 23. Astragaloside IV, a saponin from Astragalus membranaceus var. mongholicus, induces expressions of heme recycle proteins via signaling of Nrf2/ARE in cultured macrophages.
    Gong G, Yu H, Zheng Y, Qi B, He H, Yin T, Dong TT, Tsim KW.
    J Ethnopharmacol; 2021 Jan 30; 265():113389. PubMed ID: 32920134
    [Abstract] [Full Text] [Related]

  • 24. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
    Liu R, Tang C, Shen A, Luo H, Wei X, Zheng D, Sun C, Li Z, Zhu D, Li T, Wu Z.
    Oncotarget; 2016 Dec 20; 7(51):85079-85096. PubMed ID: 27835881
    [Abstract] [Full Text] [Related]

  • 25. Heme oxygenase-1/carbon monoxide axis suppresses transforming growth factor-β1-induced growth inhibition by increasing ERK1/2-mediated phosphorylation of Smad3 at Thr-179 in human hepatocellular carcinoma cell lines.
    Park SJ, Lee SK, Lim CR, Park HW, Liu F, Kim SJ, Kim BC.
    Biochem Biophys Res Commun; 2018 Apr 06; 498(3):609-615. PubMed ID: 29524413
    [Abstract] [Full Text] [Related]

  • 26. Astragaloside IV Regulates the PI3K/Akt/HO-1 Signaling Pathway and Inhibits H9c2 Cardiomyocyte Injury Induced by Hypoxia-Reoxygenation.
    Yang P, Zhou Y, Xia Q, Yao L, Chang X.
    Biol Pharm Bull; 2019 May 01; 42(5):721-727. PubMed ID: 30867343
    [Abstract] [Full Text] [Related]

  • 27. Effects of the Combination of the Main Active Components of Astragalus and Panax notoginseng on Inflammation and Apoptosis of Nerve Cell after Cerebral Ischemia-Reperfusion.
    Huang XP, Ding H, Lu JD, Tang YH, Deng BX, Deng CQ.
    Am J Chin Med; 2015 May 01; 43(7):1419-38. PubMed ID: 26477799
    [Abstract] [Full Text] [Related]

  • 28. Astragaloside IV Synergizes with Ferulic Acid to Alleviate Hepatic Fibrosis in Bile Duct-Ligated Cirrhotic Rats.
    Zhao XM, Zhang J, Liang YN, Niu YC.
    Dig Dis Sci; 2020 Oct 01; 65(10):2925-2936. PubMed ID: 31900718
    [Abstract] [Full Text] [Related]

  • 29. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
    Lou Y, Guo Z, Zhu Y, Zhang G, Wang Y, Qi X, Lu L, Liu Z, Wu J.
    J Ethnopharmacol; 2019 Jan 10; 228():82-91. PubMed ID: 30243825
    [Abstract] [Full Text] [Related]

  • 30. Protective effects of astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and in vitro effects on hepatic stellate cells.
    Liu H, Wei W, Sun WY, Li X.
    J Ethnopharmacol; 2009 Apr 21; 122(3):502-8. PubMed ID: 19429320
    [Abstract] [Full Text] [Related]

  • 31. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
    Murata M, Yoshida K, Yamaguchi T, Matsuzaki K.
    World J Gastroenterol; 2014 Nov 07; 20(41):15018-27. PubMed ID: 25386050
    [Abstract] [Full Text] [Related]

  • 32. Chalcone flavokawain A attenuates TGF-β1-induced fibrotic pathology via inhibition of ROS/Smad3 signaling pathways and induction of Nrf2/ARE-mediated antioxidant genes in vascular smooth muscle cells.
    Hseu YC, Yang TY, Li ML, Rajendran P, Mathew DC, Tsai CH, Lin RW, Lee CC, Yang HL.
    J Cell Mol Med; 2019 Feb 07; 23(2):775-788. PubMed ID: 30549180
    [Abstract] [Full Text] [Related]

  • 33. NRF2/HO-1 activation via ERK pathway involved in the anti-neuroinflammatory effect of Astragaloside IV in LPS induced microglial cells.
    Li C, Yang F, Liu F, Li D, Yang T.
    Neurosci Lett; 2018 Feb 14; 666():104-110. PubMed ID: 29273400
    [Abstract] [Full Text] [Related]

  • 34. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.
    Suwa K, Yamaguchi T, Yoshida K, Murata M, Ichimura M, Tsuneyama K, Seki T, Okazaki K.
    Cancers (Basel); 2020 Jan 24; 12(2):. PubMed ID: 31991602
    [Abstract] [Full Text] [Related]

  • 35. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis.
    Matsuzaki K.
    Histol Histopathol; 2006 Jun 24; 21(6):645-62. PubMed ID: 16528675
    [Abstract] [Full Text] [Related]

  • 36. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway.
    Wei Y, Wu Y, Feng K, Zhao Y, Tao R, Xu H, Tang Y.
    J Ethnopharmacol; 2020 Mar 01; 249():112404. PubMed ID: 31739105
    [Abstract] [Full Text] [Related]

  • 37. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
    Deng YR, Yoshida K, Jin QL, Murata M, Yamaguchi T, Tsuneyama K, Moritoki Y, Niu JQ, Matsuzaki K, Lian ZX.
    Clin Exp Immunol; 2014 Apr 01; 176(1):102-11. PubMed ID: 24372395
    [Abstract] [Full Text] [Related]

  • 38. Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling.
    Oh CJ, Kim JY, Choi YK, Kim HJ, Jeong JY, Bae KH, Park KG, Lee IK.
    PLoS One; 2012 Apr 01; 7(10):e45870. PubMed ID: 23056222
    [Abstract] [Full Text] [Related]

  • 39. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis.
    Kawamata S, Matsuzaki K, Murata M, Seki T, Matsuoka K, Iwao Y, Hibi T, Okazaki K.
    Inflamm Bowel Dis; 2011 Mar 01; 17(3):683-95. PubMed ID: 20602465
    [Abstract] [Full Text] [Related]

  • 40. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2.
    Qu X, Gao H, Zhai J, Sun J, Tao L, Zhang Y, Song Y, Hu T.
    Eur J Pharm Sci; 2020 May 30; 148():105325. PubMed ID: 32259679
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.